GlassScriptPhysician profile
Shankar Perumal
NPI 1053574681
$61,314.29
in general payments reported to CMS, 2019-2025
13 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,187 · 2020: $31K · 2021: $22K · 2022: $679 · 2023: $1,074 · 2024: $932 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $46,472.54 | 2020-2025 | |
| Ucb, INC. | $8,609.79 | 2019-2022 | |
| Livanova USA, INC. | $1,375.00 | 2019-2020 | |
| Eisai INC. | $1,258.70 | 2019-2023 | |
| Ucb Sa | $1,237.46 | 2019 | |
| Greenwich Biosciences, INC. | $646.96 | 2019-2021 | |
| Monteris Medical Corporation | $499.39 | 2022-2024 | Neuroblate |
| Neuropace, INC. | $491.28 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $263.74 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $257.04 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $94.10 | 2021 | |
| Zimmer Biomet Holdings, INC. | $92.89 | 2019-2022 | |
| Amgen INC. | $15.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shankar Perumal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.